TrialCompass TCL
Back to results
Phase 1Not yet recruitingPriority 4 · Lower priorityNCT06712173

Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

ClinicalTrials.gov

Plain-language summary

This Phase 1 trial is testing linperlisib and SHR2554 for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

linperlisib and SHR2554 (DRUG): Linperlisib doses were preset at 40mg QD and 60mg QD, while SHR2554 doses were preset at 150mg BID, 200mg BID, and 300mg BID, forming six dose groups in total.

Drugs / treatments
linperlisib and SHR2554
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

NCT06712173

Phase: Phase 1 | Status: Not yet recruiting | Priority: Lower

Plain-language summary

This Phase 1 trial is testing linperlisib and SHR2554 for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

linperlisib and SHR2554 (DRUG): Linperlisib doses were preset at 40mg QD and 60mg QD, while SHR2554 doses were preset at 150mg BID, 200mg BID, and 300mg BID, forming six dose groups in total.

Drugs / treatments: linperlisib and SHR2554

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 33 patients

Primary endpoint: Maximum Tolerated Dose (MTD) of linperlisib in combination with SHR2554

Ages: 18 Years to —

Start date: 2024-12-01 | Est. completion: 2026-03-31

Locations

0 US sites · 0 total

Contact

Tingyu Wang | wangtingyu@ihcams.ac.cn | 15692201678

Sponsor: Institute of Hematology & Blood Diseases Hospital, China (OTHER)

Tags

All T-cell lymphomas · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06712173

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.